Table 3. Patients with positive bone/bone marrow findings on fluorine-18 (18F)-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/CT.
| Number | Sex | Age (years) | H/P | Stage | BMB | FDG-avid foci | CT: bone findingsa | Response PET | Follow-up (months) | Status |
| 1 | M | 21 | MC | IV-B/LS | + | Diffuse | +ve CT | CMR | 6 | CR |
| 2 | M | 48 | MC | IV-BLS | – | Multifocal | +ve CT | CMR | 8 | CR |
| 3 | M | 59 | MC | IV-BS | – | Multifocal | +ve CT | PD | 3 | Died |
| 4 | M | 18 | MC | III-S | – | Multifocal | +ve CT | CMR | 10 | CR |
| 5 | M | 66 | NS | II-A | – | Unifocal femur | +ve CT | CMR | 4 | CR |
| 6 | M | 10 | MC | IV-S | + | Multifocal | +ve CT | PD | 9 | Che |
| 7 | F | 21 | MC | IV-BLS | – | Unifocal D-12 | –ve CT | CMR | 12 | CR |
| 8 | M | 53 | MC | II-B | – | Diffuse | –ve CT | CMR | 7 | CR |
| 9 | M | 40 | MC | IV-BSX | – | Multifocal | –ve CT | CMR | 6 | CR |
| 10 | F | 28 | NS | III-AS | – | Diffuse | –ve CT | CMR | 10 | CR |
| 11 | F | 35 | NS | III-BS | – | Unifocal L-1 | –ve CT | CMR | 8 | CR |
| 12 | M | 28 | NS | III-B | – | Multifocal | +ve CT | CMR | 6 | CR |
| 13 | M | 23 | NS | III-B | – | Diffuse | –ve CT | CMR | 6 | CR |
| 14 | M | 45 | MC | III-AS | – | Unifocal | –ve CT | CMR | 6 | CR |
| 15 | M | 40 | MC | III-S | – | Diffuse | –ve CT | CMR | 7 | CR |
| 16 | M | 43 | MC | IV-BLS | – | Multifocal | –ve CT | CMR | 6 | PR |
| 17 | M | 06 | MC | III-S | – | Multifocal | –ve CT | CMR | 9 | CR |
| 18 | M | 12 | MC | IV-LS | + | Multifocal | +ve CT | CMR | 8 | CR |
| 19 | M | 28 | MC | II-B | – | Diffuse | –ve CT | CMR | 10 | CR |
| 20 | F | 50 | MC | IV-S | – | Multifocal | –ve CT | CMR | 9 | CR |
| 21 | M | 15 | MC | III-S | – | Diffuse | –ve CT | CMR | 6 | CR |
| 22 | M | 21 | LP | IV | + | Unifocal ischium | +ve CT | CMR | 9 | CR |
| 23 | F | 24 | NS | II-AX | – | Diffuse | –ve CT | CMR | 6 | CR |
| 24 | M | 17 | MC | II-A | – | Diffuse | –ve CT | CMR | 10 | CR |
| 25 | F | 14 | MC | IV-L | + | Multifocal | –ve CT | CMR | 6 | CR |
| 26 | F | 17 | MC | IV-L | – | Unifocal ilium | +ve CT | PD | 6 | Che |
| 27 | M | 19 | MC | IV-L | – | Multifocal | –ve CT | CMR | 7 | CR |
| 28 | M | 22 | NS | IV-BS | – | Multifocal | +ve CT | CMR | 9 | CR |
| 29 | M | 23 | NS | IV-LS | + | Multifocal | –ve CT | CMR | 12 | CR |
| 30 | M | 11 | MC | III-S | – | Multifocal | +ve CT | CMR | 6 | CR |
| 31 | F | 24 | NS | IV-BL | + | Multifocal | –ve CT | CMR | 8 | CR |
| 32 | F | 29 | MC | III-A | – | Multifocal | +ve CT | CMR | 7 | CR |
| 33 | M | 49 | NS | IV-BS | + | Multifocal | +ve CT | CMR | 6 | CR |
| 34 | M | 30 | MC | IV-BS | + | Multifocal | +ve CT | CMR | 6 | CR |
| 35 | M | 26 | NS | II-BX | – | Diffuse | +ve CT | CMR | 6 | CR |
| 36 | M | 15 | MC | IV-BS | + | Multifocal | +ve CT | CMR | 8 | CR |
| 37 | M | 64 | MC | IV-BS | + | Diffuse | –ve CT | CMR | 12 | CR |
A, without B symptoms; B, B symptoms (fever, night sweats, weight loss); Che, second-line chemotherapy; CMR, complete metabolic response; CR, complete remission of Hodgkin's lymphoma; F, female; L, liver involvement; LP, lymphocyte predominant; M, male; MC, mixed cellularity; NS, nodular sclerosis; PD, progressive disease; PR, partial response; S, spleen involvement; X, bulky disease (>10 cm); −ve, negative CT of PET/CT; +ve, positive CT of PET/CT.